MedPath

Paricalcitol

Generic Name
Paricalcitol
Brand Names
Zemplar
Drug Type
Small Molecule
Chemical Formula
C27H44O3
CAS Number
131918-61-1
Unique Ingredient Identifier
6702D36OG5
Background

Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.

Indication

For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4

Associated Conditions
Secondary Hyperparathyroidism (SHPT)
Clinical Trials
Related News

A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer

Early Phase 1
Terminated
Conditions
Pancreatic Cancer
Interventions
First Posted Date
2018-05-08
Last Posted Date
2024-03-15
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Target Recruit Count
3
Registration Number
NCT03519308
Locations
🇺🇸

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)

Phase 2
Completed
Conditions
Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma
Pancreatic Adenocarcinoma
Pancreas Metastases
Adenocarcinoma
Interventions
First Posted Date
2018-01-30
Last Posted Date
2023-12-15
Lead Sponsor
HonorHealth Research Institute
Target Recruit Count
11
Registration Number
NCT03415854
Locations
🇺🇸

HonorHealth Research Institute, Scottsdale, Arizona, United States

A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer

Phase 2
Completed
Conditions
Pancreatic Cancer
Pancreas Adenocarcinoma
Advanced Pancreatic Cancer
Metastatic Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma
Interventions
Drug: placebo
First Posted Date
2017-11-06
Last Posted Date
2022-12-27
Lead Sponsor
Translational Genomics Research Institute
Target Recruit Count
24
Registration Number
NCT03331562
Locations
🇺🇸

City of Hope National Medical Center, Duarte, California, United States

🇺🇸

HonorHealth Research Institute, Scottsdale, Arizona, United States

🇺🇸

The University of Kansas Cancer Center, Westwood, Kansas, United States

and more 3 locations

A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer

Phase 1
Terminated
Conditions
Pancreatic Cancer
Interventions
First Posted Date
2017-10-04
Last Posted Date
2022-03-31
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Target Recruit Count
3
Registration Number
NCT03300921
Locations
🇺🇸

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Intravenous Paricalcitol in Chronic Hemodialysis Patients

Phase 4
Conditions
Endstage Renal Disease
Secondary Hyperparathyroidism
Interventions
First Posted Date
2017-01-18
Last Posted Date
2017-01-18
Lead Sponsor
The University of Hong Kong
Target Recruit Count
30
Registration Number
NCT03023748
Locations
🇭🇰

Queen Mary Hospital and Tung Wah Hospital, Hong Kong, Hong Kong

Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery

Phase 1
Completed
Conditions
Resectable Pancreatic Carcinoma
Stage I Pancreatic Cancer AJCC v6 and v7
Stage IA Pancreatic Cancer AJCC v6 and v7
Stage IB Pancreatic Cancer AJCC v6 and v7
Stage II Pancreatic Cancer AJCC v6 and v7
Stage IIA Pancreatic Cancer AJCC v6 and v7
Stage IIB Pancreatic Cancer AJCC v6 and v7
Interventions
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
Procedure: Therapeutic Conventional Surgery
First Posted Date
2016-10-12
Last Posted Date
2023-02-09
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
9
Registration Number
NCT02930902
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Paricalcitol Improves Anemia of Inflammation

Phase 4
Terminated
Conditions
Anemia
Interventions
Drug: Placebo
First Posted Date
2016-08-23
Last Posted Date
2024-12-09
Lead Sponsor
Hospital Son Espases
Target Recruit Count
19
Registration Number
NCT02876211
Locations
🇪🇸

Son Espases University Hospital, Palma de Mallorca, Islas Baleares, Spain

Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2
Completed
Conditions
Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
First Posted Date
2016-04-28
Last Posted Date
2024-12-10
Lead Sponsor
HonorHealth Research Institute
Target Recruit Count
35
Registration Number
NCT02754726
Locations
🇺🇸

Clinical Trials Nurse Navigator, Scottsdale, Arizona, United States

DBPC-Dose-finding-trial of Vitamin D3 for SCIT in Birch Pollen Allergic Patients.

Phase 2
Completed
Conditions
Hypersensitivity
Interventions
Drug: Placebo (for paricalcitol)
First Posted Date
2016-02-22
Last Posted Date
2018-09-04
Lead Sponsor
Laurian Jongejan
Target Recruit Count
44
Registration Number
NCT02686827
Locations
🇳🇱

Academic medical center, Amsterdam, Netherlands

Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome

Recruiting
Conditions
Alport Syndrome
Hereditary Kidney Disease
Pediatric Kidney Disease
Thin Basement Membrane Disease
Familial Benign Hematuria
Interventions
Drug: ACE-inhibitor
Drug: Angiotensin-receptor blocker (ARB)
Drug: HMG-Coenzyme inhibitor (statin)
Drug: Spironolactone or Finerenone
Drug: SGLT2 inhibitor
First Posted Date
2015-03-04
Last Posted Date
2025-03-06
Lead Sponsor
University Hospital Goettingen
Target Recruit Count
800
Registration Number
NCT02378805
Locations
🇩🇪

University Medical Center Göttingen, Göttingen, Lower Saxony, Germany

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy